Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

BiomEdit Announces Advancement of a First-of-Its-Kind Engineered Bacteria Product into Full Pivotal Development to Combat Necrotic Enteritis in Broiler Chickens


News provided by

BiomEdit

Feb 15, 2024, 07:00 ET

Share this article

Share toX

Share this article

Share toX

BiomEdit
BiomEdit

Animal Health biotech BiomEdit announced the advancement of a first-of-its-kind engineered bacteria product into full pivotal development. The product candidate – BE-101 – is a probiotic vectored antibody (pvAb™) biological and was specifically engineered to combat the damaging effects of necrotic enteritis in broiler chickens.

FISHERS, Ind., Feb. 15, 2024 /PRNewswire-PRWeb/ -- BiomEdit, an emerging animal health biotechnology company, today announced the advancement of a first-of-its-kind engineered bacteria product into full pivotal development. The product candidate – BE-101 – is a probiotic vectored antibody (pvAb™) biological and was specifically engineered to combat the damaging effects of necrotic enteritis in broiler chickens. The company is targeting conditional licensure by the United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) in 2026.

Necrotic enteritis stands as one of the most economically devastating diseases in the poultry industry, causing annual losses estimated at $6 billion worldwide, with individual outbreaks resulting in mortality rates as high as 50%. Treating necrotic enteritis effectively remains a challenge. Antibiotics are often used reactively after outbreaks occur, highlighting the need for preventive solutions. BE-101 will offer an efficient-to-deliver, novel, non-antibiotic, biological approach to combating necrotic enteritis in poultry to address poultry producers' expectations for a next-generation solution.

"We are very encouraged by the progress and positive study results of BE-101," said BiomEdit CEO Aaron Schacht. "It's a significant step forward in our mission to offer transformational solutions for poultry health and productivity through this novel biologic approach to combat necrotic enteritis."

Post this

"We are very encouraged by the progress of BE-101 and the positive results observed in our recent studies," said Aaron Schacht, CEO at BiomEdit. "This represents a significant step forward in our mission to offer transformational solutions for poultry health and productivity. By offering this novel biologic approach for producers to combat necrotic enteritis, we can help them avoid and reduce the use of antibiotics while supporting their achievement of poultry production goals."

BE-101 represents a paradigm shift in the tools available to poultry producers and veterinarians in the fight against necrotic enteritis. As a pvAb™ technology, BE-101 is an engineered bacterial consortium that delivers protective biomolecules directly to the chicken's gut. The engineered bacteria act as "probiotic vectors," supporting gut health, while simultaneously expressing antibodies that neutralize toxins produced by the Clostridium perfringens (C. perfringens) bacteria responsible for the damaging effects of necrotic enteritis.

Regulatory Pathway for Approval

In BiomEdit's collaboration with the USDA CVB, the Agency determined that the novelty of the antibody expression technology engineered into safe commensal Lactobacillus delivery strains establish eligibility for the conditional licensure pathway. BiomEdit and CVB's recent alignment on licensing plan requirements for BE-101 paves the way for future pvAb™ approaches targeting different diseases and marks a significant advancement for the development of novel biotherapeutics in animal health.

"As first-time innovations combining microbiome science and synthetic biology like BE-101 emerge, it's critical to work closely with regulatory authorities to ensure safe and efficacious products and efficient approvals," said Emily Helmes, vice president of Regulatory at BiomEdit. "We appreciate the collaboration with CVB on BE-101."

Pivotal studies are currently underway and completed studies have already demonstrated consistent and promising results. Five positive studies encompassing nearly 2,000 birds show significant reductions in necrotic enteritis-related mortality. The company is now focused on completing additional efficacy studies, scaling up and optimizing manufacturing, formulation and delivery studies, and conducting necessary safety studies to support regulatory submission.

BiomEdit recently commenced efforts for a Series B capital raise targeting sufficient funds to advance BE-101 to market and progress an exciting pipeline of several additional novel animal health projects.

About BiomEdit

BiomEdit is an emerging animal health biotechnology company that leverages a unique platform combining the leading science of the microbiome with synthetic biology to innovate novel animal health products to address challenges in livestock production and pet health. Founded through a strategic partnership in 2022 between Elanco Animal Health (NYSE: ELAN) and Ginkgo Bioworks (NYSE: DNA), the company was born from a carve-out of technology and assets from Elanco combined with access to Ginkgo's leading cell programming platform technology. BiomEdit is a private venture funded by Anterra Capital, Viking Global Investors, Ferment, and Nutreco Ventures. In 2022, BiomEdit was recognized by S&P Global Animal Health as Best Start-up in Animal Health and CEO Aaron Schacht as 2023's Visionary CEO in its annual animal health industry awards. In November 2023, BiomEdit received a $4.5M grant from the Bill & Melinda Gates Foundation to accelerate research and development of a portfolio of novel microbiome-based solutions to reduce methane emissions that also enhance feed efficiency for beef and dairy cattle. The company also announced a first-of-its-kind collaboration with Athian, the world's first cloud-based carbon marketplace for the livestock industry, to develop sustainability protocols and products in parallel. For more information, visit www.biomedit.com.

Wade B., Keyburn A. L., Seemann T., Rood J. I., Moore R. J. (2015). Binding of Clostridium perfringens to Collagen Correlates with the Ability to Cause Necrotic Enteritis in Chickens. Vet. Microbiol. 180 (3-4), 299–303. doi:10.1016/j.vetmic.2015.09.019

https://www.merckvetmanual.com/poultry/necrotic-enteritis/necrotic-enteritis-in-poultry

Media Contact

Julie Lawless, BiomEdit, 1 6155855861, [email protected], www.biomedit.com 

SOURCE BiomEdit

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.